Charles Schwab Investment Management Inc. Grows Position in Liquidia Co. (NASDAQ:LQDA)

Charles Schwab Investment Management Inc. increased its holdings in shares of Liquidia Co. (NASDAQ:LQDA) by 9.8% during the fourth quarter, Holdings Channel.com reports. The fund owned 428,570 shares of the company’s stock after buying an additional 38,313 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Liquidia were worth $5,040,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Steward Partners Investment Advisory LLC purchased a new stake in Liquidia during the 4th quarter worth approximately $59,000. Walleye Trading LLC increased its stake in shares of Liquidia by 54.7% in the 3rd quarter. Walleye Trading LLC now owns 13,201 shares of the company’s stock worth $132,000 after acquiring an additional 4,670 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Liquidia by 43.5% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,708 shares of the company’s stock valued at $187,000 after buying an additional 5,669 shares during the period. DMC Group LLC boosted its stake in Liquidia by 17.4% during the fourth quarter. DMC Group LLC now owns 16,302 shares of the company’s stock worth $192,000 after buying an additional 2,419 shares during the period. Finally, Intech Investment Management LLC purchased a new position in shares of Liquidia during the third quarter worth $195,000. 64.54% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Scotiabank lifted their target price on Liquidia from $30.00 to $34.00 and gave the company a “sector outperform” rating in a report on Thursday, March 20th. Needham & Company LLC boosted their target price on Liquidia from $19.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, March 20th. HC Wainwright reissued a “buy” rating and set a $29.00 price objective on shares of Liquidia in a research report on Thursday, March 20th. Finally, Wells Fargo & Company assumed coverage on Liquidia in a report on Friday, December 20th. They set an “overweight” rating and a $20.00 price target for the company. One investment analyst has rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Liquidia has an average rating of “Buy” and a consensus price target of $26.63.

Insiders Place Their Bets

In other Liquidia news, insider Rajeev Saggar sold 6,249 shares of the company’s stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total value of $73,613.22. Following the transaction, the insider now directly owns 270,388 shares in the company, valued at approximately $3,185,170.64. This represents a 2.26 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Michael Kaseta sold 23,370 shares of the firm’s stock in a transaction that occurred on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total transaction of $275,298.60. Following the sale, the chief financial officer now owns 401,755 shares in the company, valued at approximately $4,732,673.90. This trade represents a 5.50 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 71,245 shares of company stock worth $843,326. Insiders own 30.10% of the company’s stock.

Liquidia Trading Down 0.4 %

Shares of LQDA opened at $15.60 on Wednesday. Liquidia Co. has a twelve month low of $8.26 and a twelve month high of $16.81. The firm has a market capitalization of $1.33 billion, a P/E ratio of -9.57 and a beta of 0.07. The firm’s 50-day moving average is $14.95 and its two-hundred day moving average is $12.32.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. The firm had revenue of $2.92 million for the quarter, compared to analysts’ expectations of $4.60 million. Analysts predict that Liquidia Co. will post -1.51 EPS for the current year.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).